AXGN Axogen, Inc.
Nasdaq · SEC CIK 805928 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $19.88M 31 sales by 12 insiders
- Filings on record
- 236 since 2021-07-21, latest 2026-09-04 16:08
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Began Marc A | EVP, GC | — | $3.88M |
| Burke William P. Mr. | Dir | — | $2.82M |
| Weiler Kathy Johnson | Dir | — | $2.74M |
| DALE MICHAEL D | CEO | — | $2.67M |
| Wendell Amy McBride | Dir | — | $2.00M |
| JOHNSON JOHN | Dir | — | $1.87M |
| TYNDALL JOSEPH A. | Dir | — | $951.8K |
| Hartley Lindsey Marie | CFO | — | $942.2K |
| DeVinney Erick Wayne | Chief Innovation Off | — | $780.6K |
| THOMAS PAUL | Dir | — | $633.6K |
Transactions 312
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-20 | 2022-07-18 | AXGN | Scopelianos Angelo | Chief R, D Off | A - Grant | $0.00 | +2,571 | 22.8K | +13% | $0 | |
| 2022-07-20 | 2022-07-18 | AXGN | MARIANI PETER J | EVP, CFO | A - Grant | $0.00 | +3,710 | 38.3K | +11% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | MARIANI PETER J | EVP, CFO | D - Sale to Iss | $8.40 | -947 | 40.3K | -2% | -$7,955 | |
| 2022-07-20 | 2022-07-18 | AXGN | Sandberg Eric | Chief Commercial Off | A - Grant | $0.00 | +4,408 | 17.2K | +34% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | Sandberg Eric | Chief Commercial Off | D - Sale to Iss | $8.40 | -1,125 | 16.1K | -7% | -$9,450 | |
| 2022-07-20 | 2022-07-19 | AXGN | Zaderej Karen L. | CEO, Dir | D - Sale to Iss | $8.40 | -9,081 | 981.5K | -0.9% | -$76.3K | |
| 2022-07-20 | 2022-07-18 | AXGN | Zaderej Karen L. | CEO, Dir | A - Grant | $0.00 | +22.1K | 988.4K | +2% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | MARTINEZ MARIA D. | CHRO | D - Sale to Iss | $8.40 | -657 | 18.2K | -3% | -$5,519 | |
| 2022-07-20 | 2022-07-18 | AXGN | MARTINEZ MARIA D. | CHRO | A - Grant | $0.00 | +2,571 | 18.9K | +16% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | Billet Isabelle | Chief Strategy, BD Off | D - Sale to Iss | $8.40 | -751 | 24.2K | -3% | -$6,308 | |
| 2022-07-20 | 2022-07-18 | AXGN | Billet Isabelle | Chief Strategy, BD Off | A - Grant | $0.00 | +2,571 | 24.3K | +12% | $0 | |
| 2022-07-20 | 2022-07-18 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | A - Grant | $0.00 | +1,579 | 94.2K | +2% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | D - Sale to Iss | $8.40 | -405 | 96.8K | -0.4% | -$3,402 | |
| 2022-07-20 | 2022-07-18 | AXGN | Donovan Michael Patrick | VP Ops | A - Grant | $0.00 | +2,571 | 64.5K | +4% | $0 | |
| 2022-07-20 | 2022-07-19 | AXGN | Donovan Michael Patrick | VP Ops | D - Sale to Iss | $8.40 | -657 | 63.9K | -1% | -$5,519 | |
| D | 2022-06-03 | 2022-06-01 | AXGN | Freitag Gregory Gene | Dir | M - OptEx | $0.00 | +3,036 | 358.8K | +0.9% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | Levine Alan M | Dir | M - OptEx | $0.00 | +3,036 | 11.8K | +35% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | Ottinger Bradley | GC, CCO | M - OptEx | $0.00 | +15.5K | 18.6K | +504% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | Ottinger Bradley | GC, CCO | F - Tax | $0.00 | -3,775 | 14.8K | -20% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | NEELS GUIDO J | Dir | M - OptEx | $0.00 | +3,036 | 51.8K | +6% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | THOMAS PAUL | Dir | A - Grant | $0.00 | +3,036 | 3,036 | New | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | Wendell Amy McBride | Dir | M - OptEx | $0.00 | +3,036 | 35.1K | +9% | $0 |
| D | 2022-06-03 | 2022-06-01 | AXGN | Gold Mark Stephen | Dir | M - OptEx | $0.00 | +3,036 | 305.5K | +1% | $0 |
| D | 2022-04-01 | 2022-03-30 | AXGN | Blackford Quentin S. | Dir | M - OptEx | $0.00 | +3,036 | 27.3K | +12% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Scopelianos Angelo | Chief R, D Off | M - OptEx | $0.00 | +11.0K | 22.9K | +92% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Scopelianos Angelo | Chief R, D Off | F - Tax | $7.97 | -2,770 | 20.2K | -12% | -$22.1K |
| D | 2022-03-18 | 2022-03-16 | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $0.00 | +25.9K | 966.3K | +3% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Donovan Michael Patrick | VP Ops | M - OptEx | $0.00 | +6,000 | 63.5K | +10% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Donovan Michael Patrick | VP Ops | F - Tax | $7.97 | -1,512 | 61.9K | -2% | -$12.1K |
| D | 2022-03-18 | 2022-03-16 | AXGN | MARIANI PETER J | EVP, CFO | F - Tax | $7.97 | -2,769 | 34.6K | -7% | -$22.1K |
| D | 2022-03-18 | 2022-03-16 | AXGN | MARIANI PETER J | EVP, CFO | M - OptEx | $0.00 | +11.0K | 37.4K | +42% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | M - OptEx | $0.00 | +6,000 | 25.8K | +30% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | F - Tax | $7.97 | -1,502 | 24.3K | -6% | -$12.0K |
| D | 2022-03-18 | 2022-03-16 | AXGN | Ottinger Bradley | GC, CCO | A - Grant | $0.00 | +2,563 | 3,721 | +221% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Ottinger Bradley | GC, CCO | F - Tax | $7.97 | -648 | 3,073 | -17% | -$5,165 |
| D | 2022-03-18 | 2022-03-16 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $0.00 | +6,000 | 94.1K | +7% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $7.97 | -1,497 | 92.6K | -2% | -$11.9K |
| DM | 2022-03-18 | 2022-03-16 | AXGN | MARTINEZ MARIA D. | CHRO | M - OptEx | $0.00 | +12.9K | 19.5K | +193% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | MARTINEZ MARIA D. | CHRO | F - Tax | $7.97 | -3,239 | 16.3K | -17% | -$25.8K |
| D | 2022-03-18 | 2022-03-16 | AXGN | Sandberg Eric | Chief Commercial Off | M - OptEx | $0.00 | +6,000 | 14.3K | +72% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Sandberg Eric | Chief Commercial Off | F - Tax | $7.97 | -1,512 | 12.8K | -11% | -$12.1K |
| D | 2022-03-18 | 2022-03-16 | AXGN | Billet Isabelle | Chief Strategy, BD Off | M - OptEx | $0.00 | +8,500 | 24.2K | +54% | $0 |
| D | 2022-03-18 | 2022-03-16 | AXGN | Billet Isabelle | Chief Strategy, BD Off | F - Tax | $7.97 | -2,447 | 21.8K | -10% | -$19.5K |
| DM | 2022-02-24 | 2022-02-22 | AXGN | Donovan Michael Patrick | VP Ops | M - OptEx | $5.21 | +15.0K | 57.5K | +35% | +$78.2K |
| 2022-02-17 | 2022-02-15 | AXGN | MARIANI PETER J | EVP, CFO | F - Tax | $8.42 | -950 | 26.4K | -3% | -$7,999 | |
| 2022-02-17 | 2022-02-15 | AXGN | MARIANI PETER J | EVP, CFO | A - Grant | $0.00 | +3,157 | 27.3K | +13% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Sandberg Eric | Chief Commercial Off | A - Grant | $0.00 | +2,531 | 9,072 | +39% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Sandberg Eric | Chief Commercial Off | F - Tax | $8.42 | -762 | 8,310 | -8% | -$6,416 | |
| 2022-02-17 | 2022-02-15 | AXGN | Zaderej Karen L. | CEO, Dir | A - Grant | $0.00 | +14.0K | 940.4K | +2% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Billet Isabelle | Chief Strategy, BD Off | A - Grant | $0.00 | +1,325 | 16.2K | +9% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Billet Isabelle | Chief Strategy, BD Off | F - Tax | $8.42 | -447 | 15.7K | -3% | -$3,764 | |
| 2022-02-17 | 2022-02-15 | AXGN | Scopelianos Angelo | Chief R, D Off | A - Grant | $0.00 | +1,325 | 12.3K | +12% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Scopelianos Angelo | Chief R, D Off | F - Tax | $8.42 | -400 | 11.9K | -3% | -$3,368 | |
| 2022-02-17 | 2022-02-15 | AXGN | Donovan Michael Patrick | VP Ops | A - Grant | $0.00 | +675 | 42.7K | +2% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | Donovan Michael Patrick | VP Ops | F - Tax | $8.42 | -205 | 42.5K | -0.5% | -$1,726 | |
| 2022-02-17 | 2022-02-15 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | F - Tax | $8.42 | -357 | 19.8K | -2% | -$3,006 | |
| 2022-02-17 | 2022-02-15 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | A - Grant | $0.00 | +1,181 | 20.2K | +6% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | A - Grant | $0.00 | +1,181 | 88.4K | +1% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $8.42 | -357 | 88.1K | -0.4% | -$3,006 | |
| 2022-02-17 | 2022-02-15 | AXGN | MARTINEZ MARIA D. | CHRO | A - Grant | $0.00 | +1,325 | 7,056 | +23% | $0 | |
| 2022-02-17 | 2022-02-15 | AXGN | MARTINEZ MARIA D. | CHRO | F - Tax | $8.42 | -400 | 6,656 | -6% | -$3,368 | |
| D | 2021-12-29 | 2021-12-27 | AXGN | MARIANI PETER J | EVP, CFO | F - Tax | $9.74 | -648 | 24.1K | -3% | -$6,312 |
| D | 2021-12-29 | 2021-12-27 | AXGN | MARIANI PETER J | EVP, CFO | M - OptEx | $0.00 | +2,625 | 24.8K | +12% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Scopelianos Angelo | Chief R, D Off | M - OptEx | $0.00 | +1,150 | 11.3K | +11% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Scopelianos Angelo | Chief R, D Off | F - Tax | $9.74 | -286 | 11.0K | -3% | -$2,786 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Billet Isabelle | Chief Strategy, BD Off | M - OptEx | $0.00 | +1,150 | 14.5K | +9% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Billet Isabelle | Chief Strategy, BD Off | F - Tax | $9.74 | -326 | 14.2K | -2% | -$3,175 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Donovan Michael Patrick | VP Ops | M - OptEx | $0.00 | +1,150 | 42.3K | +3% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Donovan Michael Patrick | VP Ops | F - Tax | $9.74 | -286 | 42.0K | -0.7% | -$2,786 |
| D | 2021-12-29 | 2021-12-27 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $9.74 | -187 | 87.2K | -0.2% | -$1,821 |
| D | 2021-12-29 | 2021-12-27 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $0.00 | +750 | 87.4K | +0.9% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | M - OptEx | $0.00 | +1,150 | 17.7K | +7% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | F - Tax | $9.74 | -286 | 17.5K | -2% | -$2,786 |
| D | 2021-12-29 | 2021-12-27 | AXGN | MARTINEZ MARIA D. | CHRO | M - OptEx | $0.00 | +1,150 | 6,017 | +24% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | MARTINEZ MARIA D. | CHRO | F - Tax | $9.74 | -286 | 5,731 | -5% | -$2,786 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $0.00 | +4,400 | 927.4K | +0.5% | $0 |
| D | 2021-12-29 | 2021-12-27 | AXGN | Zaderej Karen L. | CEO, Dir | F - Tax | $9.74 | -1,752 | 925.7K | -0.2% | -$17.1K |
| D | 2021-12-22 | 2021-12-20 | AXGN | MARIANI PETER J | EVP, CFO | F - Tax | $9.24 | -757 | 22.2K | -3% | -$6,995 |
| D | 2021-12-22 | 2021-12-20 | AXGN | MARIANI PETER J | EVP, CFO | M - OptEx | $0.00 | +1,900 | 22.9K | +9% | $0 |
| D | 2021-12-22 | 2021-12-20 | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $0.00 | +3,125 | 924.3K | +0.3% | $0 |
| D | 2021-12-22 | 2021-12-20 | AXGN | Zaderej Karen L. | CEO, Dir | F - Tax | $9.24 | -1,243 | 923.0K | -0.1% | -$11.5K |
| D | 2021-12-22 | 2021-12-20 | AXGN | Donovan Michael Patrick | VP Ops | M - OptEx | $0.00 | +375 | 41.2K | +0.9% | $0 |
| D | 2021-12-22 | 2021-12-20 | AXGN | Donovan Michael Patrick | VP Ops | F - Tax | $9.24 | -95 | 41.1K | -0.2% | -$877.80 |
| D | 2021-12-22 | 2021-12-20 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | M - OptEx | $0.00 | +375 | 16.7K | +2% | $0 |
| D | 2021-12-22 | 2021-12-20 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | F - Tax | $9.24 | -95 | 16.6K | -0.6% | -$877.80 |
| D | 2021-12-22 | 2021-12-20 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $9.24 | -144 | 86.7K | -0.2% | -$1,331 |
| D | 2021-12-22 | 2021-12-20 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $0.00 | +575 | 86.8K | +0.7% | $0 |
| D | 2021-12-17 | 2021-12-15 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | M - OptEx | $3.67 | +10.0K | 90.4K | +12% | +$36.7K |
| D | 2021-12-17 | 2021-12-15 | AXGN | DeVinney Erick Wayne | VP Peripheral Nerve Science | F - Tax | $8.80 | -4,171 | 86.3K | -5% | -$36.7K |
| D | 2021-11-29 | 2021-11-24 | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $8.95 | +52.4K | 921.1K | +6% | +$468.8K |
| DM | 2021-08-16 | 2021-08-12+ | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $3.88 | +54.8K | 868.8K | +7% | +$212.7K |
| D | 2021-08-10 | 2021-08-10 | AXGN | Zaderej Karen L. | CEO, Dir | M - OptEx | $5.09 | +75.0K | 855.0K | +10% | +$381.8K |
| DM | 2021-08-10 | 2021-08-06 | AXGN | Zaderej Karen L. | CEO, Dir | S - Sale+OE | $18.47 | -41.0K | 814.0K | -5% | -$757.2K |
| 2021-07-23 | 2021-07-21 | AXGN | Donovan Michael Patrick | VP Ops | S - Sale | $20.04 | -1,935 | 40.8K | -5% | -$38.8K | |
| 2021-07-21 | 2021-07-20 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | F - Tax | $19.20 | -637 | 16.3K | -4% | -$12.2K | |
| 2021-07-21 | 2021-07-19 | AXGN | Friedman Mark Louis | VP Regulatory Affairs, Policy | A - Grant | $0.00 | +2,572 | 16.9K | +18% | $0 | |
| 2021-07-21 | 2021-07-20 | AXGN | MARTINEZ MARIA D. | CHRO | F - Tax | $19.20 | -637 | 4,867 | -12% | -$12.2K | |
| 2021-07-21 | 2021-07-19 | AXGN | MARTINEZ MARIA D. | CHRO | A - Grant | $0.00 | +2,572 | 5,504 | +88% | $0 | |
| 2021-07-21 | 2021-07-19 | AXGN | Billet Isabelle | Chief Strategy, BD Off | A - Grant | $0.00 | +2,572 | 14.1K | +22% | $0 | |
| 2021-07-21 | 2021-07-20 | AXGN | Billet Isabelle | Chief Strategy, BD Off | F - Tax | $19.20 | -728 | 13.4K | -5% | -$14.0K |
Purchase Sale Sale after option exercise All abbreviations